ABL Bio's FY2025 revenue of ₩79.3bn was 95.5% earned in a single quarter, and the following quarter booked exactly zero, which is what a milestone line looks like.
No news written yet.
| Period | 298380 | KOSDAQ | Difference |
|---|---|---|---|
| 1 week | -7.2% | -3.0% | -4.2% |
| 1 month | -11.2% | +4.2% | -15.4% |
| 3 months | -32.6% | -22.5% | -10.1% |
| 6 months | -53.3% | -16.9% | -36.4% |
| Year to date | -64.3% | -12.1% | -52.2% |
| 1 year | -25.2% | +1.0% | -26.2% |
Closed at 6% of the way from its 52-week low (₩60,800) to its 52-week high (₩245,500).
ABL Bio develops bispecific antibodies and a shuttle technology meant to carry drugs across the blood-brain barrier, the obstacle that has defeated many treatments for brain disease. It licensed that platform to GSK and has partnered with Sanofi on neurodegenerative programs, so much of its value sits in milestones owed by large Western drugmakers. It runs its own oncology pipeline alongside those deals. US investors can assess it partly through the development timelines its partners disclose.
| Sector | Biopharma | Employees | |
| Market | KOSDAQ | Founded | |
| Korean name | 에이비엘바이오 | Head office |
| Symbol | Last Price |
|---|---|
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |
| 310210Voronoi, Inc. | ₩153,000 +3.9% |